AvantGuard, Inc. is thrilled to announce a major funding milestone, having successfully raised $8,000,000 to further advance our mission of revolutionizing pathogen protection. Formerly known as Halomine, AvantGuard™ has emerged from its Cornell University roots as a leading innovator in the fight against harmful pathogens, leveraging cutting-edge technology to offer durable, long-term protection against viruses, bacteria, and fungi/mold. Our proprietary combinations of specialty molecules and polymers are uniquely tailored to extend the antimicrobial efficacy of chlorine—a standard disinfectant—allowing it to safeguard surfaces for up to a month, a dramatic improvement over the temporary 15-minute protection offered by conventional disinfectants. This breakthrough is set to transform industries such as healthcare, food processing, and hospitality where the stakes are extraordinarily high; consider that hospital-acquired infections and food-borne illnesses cost the global economy over $100 billion annually.
The new funding will be dedicated to scaling our manufacturing capabilities, enhancing research and development, and expanding our market presence nationally and internationally. With strong collaborations already in place with renowned universities and research institutions, as well as a robust licensing agreement for N-halamine technology from Cornell and Auburn University, this capital injection will accelerate our mission to deliver safer environments worldwide. We are immensely grateful to our investors and partners for their confidence in our innovative solutions and for sharing our vision of a more protected future. To learn more about our breakthrough technology and how AvantGuard is redefining pathogen defense, please visit our website at https://www.avantguardinc.com/.
.png&w=3840&q=75)
